Array BioPharma announced that John A. Orwin, CEO of Affymax, Inc., has joined the company’s Board of Directors. This development is part of Array’s continued evolution toward late-stage development and commercialization.
Throughout his career, Mr. Orwin has built successful businesses and commercialized a range of blockbuster products. Mr. Orwin has served as Affymax’s CEO since 2011, after joining the company in 2010 as its COO. At Affymax, he led the approval and launch of Omontys®, a hematology product for the treatment of anemia in chronic kidney disease. Prior to joining Affymax, he led Genentech’s BioOncology business unit and grew a portfolio of cancer-fighting products to over $7 billion in U.S. sales.